NASDAQ:BBIO - Nasdaq - US10806X1028 - Common Stock - Currency: USD
32.26
-0.84 (-2.54%)
The current stock price of BBIO is 32.26 USD. In the past month the price decreased by -11.42%. In the past year, price increased by 15.17%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.83 | 323.41B | ||
AMGN | AMGEN INC | 13.41 | 149.70B | ||
GILD | GILEAD SCIENCES INC | 14.01 | 134.89B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.30B | ||
REGN | REGENERON PHARMACEUTICALS | 13.36 | 63.90B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.23B | ||
ARGX | ARGENX SE - ADR | 98.17 | 35.18B | ||
ONC | BEIGENE LTD-ADR | 6.15 | 25.99B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.45B | ||
NTRA | NATERA INC | N/A | 22.01B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.34B | ||
BIIB | BIOGEN INC | 8.06 | 18.69B |
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. The company is headquartered in Palo Alto, California and currently employs 725 full-time employees. The company went IPO on 2019-06-27. The company discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. The company also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
BRIDGEBIO PHARMA INC
3160 Porter Dr., Suite 250
Palo Alto CALIFORNIA 94301 US
CEO: Neil Kumar
Employees: 725
Phone: 16503919740
The current stock price of BBIO is 32.26 USD. The price decreased by -2.54% in the last trading session.
The exchange symbol of BRIDGEBIO PHARMA INC is BBIO and it is listed on the Nasdaq exchange.
BBIO stock is listed on the Nasdaq exchange.
24 analysts have analysed BBIO and the average price target is 60.44 USD. This implies a price increase of 87.34% is expected in the next year compared to the current price of 32.26. Check the BRIDGEBIO PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BRIDGEBIO PHARMA INC (BBIO) has a market capitalization of 6.13B USD. This makes BBIO a Mid Cap stock.
BRIDGEBIO PHARMA INC (BBIO) currently has 725 employees.
BRIDGEBIO PHARMA INC (BBIO) has a support level at 32.05 and a resistance level at 33.31. Check the full technical report for a detailed analysis of BBIO support and resistance levels.
The Revenue of BRIDGEBIO PHARMA INC (BBIO) is expected to grow by 87.39% in the next year. Check the estimates tab for more information on the BBIO EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BBIO does not pay a dividend.
BRIDGEBIO PHARMA INC (BBIO) will report earnings on 2025-07-30, before the market open.
BRIDGEBIO PHARMA INC (BBIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.77).
The outstanding short interest for BRIDGEBIO PHARMA INC (BBIO) is 14.2% of its float. Check the ownership tab for more information on the BBIO short interest.
ChartMill assigns a technical rating of 1 / 10 to BBIO. When comparing the yearly performance of all stocks, BBIO turns out to be only a medium performer in the overall market: it outperformed 65.18% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to BBIO. BBIO may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months BBIO reported a non-GAAP Earnings per Share(EPS) of -3.77. The EPS decreased by -17.08% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -75.76% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 82% to BBIO. The Buy consensus is the average rating of analysts ratings from 24 analysts.
For the next year, analysts expect an EPS growth of -4.53% and a revenue growth 87.39% for BBIO